{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T13:10:09Z","timestamp":1745932209322,"version":"3.40.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bulcan.2024.12.011","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T12:12:30Z","timestamp":1736597550000},"page":"469-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient views on continued immune checkpoint inhibition following progression in advanced melanoma: A qualitative study"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-5219","authenticated-orcid":false,"given":"Chlo\u00e9","family":"Prod\u2019homme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Sena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Forestier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozenn","family":"Le Berre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Desmedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licia","family":"Touzet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2024.12.011_bib0205","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0210","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","article-title":"Immunotherapy of melanoma: facts and hopes","volume":"25","author":"Weiss","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0215","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","article-title":"Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?","volume":"40","author":"Eggermont","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0220","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0230","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0235","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials","volume":"3","author":"Long","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0240","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","article-title":"Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0245","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cllc.2019.02.001","article-title":"Safety and efficacy of nivolumab in patients with advanced non-small-cell lung cancer treated beyond progression","volume":"20","author":"Ricciuti","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0250","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.jtho.2018.08.2027","article-title":"Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK Study","volume":"13","author":"Gandara","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0255","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","article-title":"Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis","volume":"19","author":"Beaver","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0260","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","article-title":"Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma","volume":"67","author":"Schadendorf","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0265","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/annonc\/mdw265","article-title":"Effect of nivolumab on health-related quality of life in patients with treatment-na\u00efve advanced melanoma: results from the phase III CheckMate 066 study","volume":"27","author":"Long","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0270","doi-asserted-by":"crossref","first-page":"e1190","DOI":"10.1634\/theoncologist.2018-0820","article-title":"Balancing the hype with reality: what do patients with advanced melanoma consider when making the decision to have immunotherapy?","volume":"24","author":"Wong","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0275","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1001\/jama.299.22.2667","article-title":"The role of chemotherapy at the end of life: \u201cwhen is enough, enough?\u201d","volume":"299","author":"Harrington","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0280","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s00432-020-03336-1","article-title":"Patient expectations are better for immunotherapy than traditional chemotherapy for cancer","volume":"146","author":"Ihrig","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0285","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0290","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0295","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/pcmr.12647","article-title":"Quality-of-life outcomes in patients with advanced melanoma: a review of the literature","volume":"30","author":"Malkhasyan","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0300","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00520-017-3621-z","article-title":"Patient perspectives on ipilimumab across the melanoma treatment trajectory","volume":"25","author":"Shuk","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0305","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0310","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1002\/cam4.3191","article-title":"Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease","volume":"9","author":"Weiss","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0315","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7525-10-66","article-title":"Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment","volume":"10","author":"Revicki","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0320","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1097\/NCC.0000000000000683","article-title":"Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: \u201creal-world\u201d data","volume":"43","author":"Milne","year":"2020","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0325","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/CMR.0000000000000973","article-title":"Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort","volume":"35","author":"Macaire","year":"2024","journal-title":"Melanoma Res"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0330","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jaad.2020.10.048","article-title":"Utilization of palliative therapy for metastatic melanoma in the United States","volume":"85","author":"Tripathi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0335","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S1478951515000917","article-title":"The positioning of palliative care in acute care: a multiperspective qualitative study in the context of metastatic melanoma","volume":"14","author":"Fox","year":"2016","journal-title":"Palliat Support Care"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0340","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/0269216320916154","article-title":"Palliative care in the context of immune and targeted therapies: a qualitative study of bereaved carers\u2019 experiences in metastatic melanoma","volume":"34","author":"Fox","year":"2020","journal-title":"Palliat Med"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0345","first-page":"222","article-title":"Collaboration(s)\u00a0: d\u00e9marche de r\u00e9flexion \u00e9thique pour des soins palliatifs pr\u00e9coces en onco-dermatologie","volume":"21","author":"Le Berre","year":"2022","journal-title":"Med Palliat"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0350","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"year":"1966","series-title":"Awareness of dying","author":"Glaser","key":"10.1016\/j.bulcan.2024.12.011_bib0355"},{"year":"2007","series-title":"Grounded theory. Blackwell Encycl. Sociol.","author":"Charmaz","key":"10.1016\/j.bulcan.2024.12.011_bib0360"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0365","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0370","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S1470-2045(18)30415-7","article-title":"Integration of oncology and palliative care: a Lancet Oncology Commission","volume":"19","author":"Kaasa","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0375","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jpsychores.2018.10.016","article-title":"Defense mechanisms in cancer patients: a systematic review","volume":"115","author":"Di Giuseppe","year":"2018","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0380","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.10.005","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: a systematic review and meta-analysis","volume":"159","author":"Boutros","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0385","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","article-title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","volume":"86","author":"Petrella","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0390","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/pon.4290","article-title":"Systematic review of psychosocial outcomes for patients with advanced melanoma","volume":"26","author":"Dunn","year":"2017","journal-title":"Psychooncology"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0395","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00520-017-4025-9","article-title":"Humanistic burden of disease for patients with advanced melanoma in Canada","volume":"26","author":"Cheung","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bulcan.2024.12.011_bib0400","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00520-018-4316-9","article-title":"Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada","volume":"27","author":"Cheung","year":"2019","journal-title":"Support Care Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124005150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124005150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T12:45:09Z","timestamp":1745930709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124005150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0007455124005150"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.12.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient views on continued immune checkpoint inhibition following progression in advanced melanoma: A qualitative study","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}